RT Journal Article
SR Electronic
T1 Detection of asymptomatic SARS-CoV-2 exposed individuals by a sensitive S-based ELISA
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.02.20120477
DO 10.1101/2020.06.02.20120477
A1 Ebba Rosendal
A1 Julia Wigren Byström
A1 Remigius Gröning
A1 Yong-Dae Gwon
A1 Emma Nilsson
A1 Atin Sharma
A1 Akbar Espaillat
A1 Leo Hanke
A1 Therese Thunberg
A1 Gerald McInerney
A1 Andrea Puhar
A1 Felipe Cava
A1 Gunilla B Karlsson Hedestam
A1 Tor Monsen
A1 Fredrik Elgh
A1 Bert Blomkvist
A1 Ingrid Marklund
A1 Clas Ahlm
A1 Magnus Evander
A1 Johan Normark
A1 Anders Johansson
A1 Anna K Överby
A1 Mattias NE Forsell
YR 2020
UL http://medrxiv.org/content/early/2020/06/04/2020.06.02.20120477.abstract
AB To assess the current coronavirus pandemic, there is a pressing need to determine the exposure and seroconversion to SARS-CoV-2 on a local and global level. Here, we demonstrate a sensitive and specific S-protein based assay that is well suited for detection of weak SARS-CoV-2-directed IgG responses, and that could identify exposed individuals with asymptomatic infection without the requirement of PCR diagnostics. Our results raise the possibility that ongoing population-based studies using less sensitive state-of-the-art serological assays may significantly underestimate the frequency of exposure and seroconversion to SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementIntramural funds from the Medical Faculty, Umea University AN2.2.1.2-76-14 to MF and in part by the National Institutes of health U19AI142777 to MNEF and CA, and The Swedish Science Council 2018-05851, 2017-02438, Kempestiftelserna SMK-1654 and JCK-1827 to AKO. Region Vasterbotten and Umea University to CA, Swedish Science Council and the Knut and Alice Wallenberg foundation to FC. AS is a postdoctoral fellow wihin the MIMS Excellence by Choice programme, under the patronage of Emmanuelle Charpentier SMK1532.2.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All serum samples within this study were collected for clinical purposes within the realm of providing healthcare to patients in Region Vasterbotten, Sweden and stored at the Department of Laboratory Medicine, Umea University Hospital. The research was carried out according to The Code of Ethics of the World Medical Association (Declaration of Helsinki). Ethical permission was obtained from the Swedish Ethical review authority (No: 2020-01557).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available within the article or its supplementary materials